Holen Sie sich die Stockscreener-App
12.19
2.48%
-0.33
Schlusskurs vom Vortag:
$12.52
Offen:
$12.5
24-Stunden-Volumen:
751.72K
Relative Volume:
0.42
Marktkapitalisierung:
$1.08B
Einnahmen:
$71.64M
Nettoeinkommen (Verlust:
$-294.57M
KGV:
-3.641
EPS:
-3.348
Netto-Cashflow:
$-84.46M
1W Leistung:
-6.86%
1M Leistung:
+27.59%
6M Leistung:
+30.03%
1J Leistung:
+52.43%
1-Tages-Spanne:
$12.15
$12.61
1-Wochen-Bereich:
$12.15
$13.29
52-Wochen-Spanne:
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
12.19 | 1.11B | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.02 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.69 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.08 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions By Investing.com - Investing.com India
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - Yahoo Finance
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
Eli Lilly is among investors in a new diabetes company with $50 million - Stock Titan
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth - TradingView
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth by 2028 - TradingView
Kura Oncology at Wells Fargo conference: launch gains and pipeline breadth - Investing.com
Kura Oncology Names Jennifer Fulk Chief Financial Officer - Minichart
Kura Oncology, Inc. Announces Chief Financial Officer Changes, Effective September 8, 2026 - marketscreener.com
Kura Oncology Names Jennifer Fulk Finance Chief - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Jennifer Fulk named CFO of Kura Oncology, replacing Troy E. Wilson and Thomas Doyle - TradingView
A former Eli Lilly executive takes Kura's top finance job - Stock Titan
Four new hires get options to buy 48,450 Kura shares - Stock Titan
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price-Driven Insight from (KURA) for Rule-Based Strategy - Stock Traders Daily
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run - Yahoo Finance
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know - TradingView
Kura Oncology to Participate in Three Investor Conferences in September - GlobeNewswire
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase - Barron's
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? - qz.com
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects - Seeking Alpha
Kura Oncology Shares Rise After CEO Purchases 100,000 Shares - marketscreener.com
Kura Oncology stock jumps after CEO buys $1.24M in shares - Investing.com Nigeria
Kura Oncology CCO Brian Powl sells $51,663 in shares By Investing.com - Investing.com Nigeria
Kura Oncology CEO Troy Wilson buys $1.24 million Kura shares By Investing.com - Investing.com South Africa
The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today - webull.com
Citizens reiterates Kura Oncology stock rating on launch progress - Investing.com
UBS Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology (KURA) Chief Legal Officer Teresa Bair Sells 31,48 - GuruFocus
Kura Oncology (NASDAQ:KURA) Insider Sells 31,487 Shares - MarketBeat
Kura Oncology (NASDAQ: KURA) affiliate flags 4,345-share Rule 144 sale - Stock Titan
Kura Oncology (KURA) counsel offloads shares via 10b5-1 plan - Stock Titan
Great Lakes Advisors LLC Invests $2.85 Million in Kura Oncology, Inc. $KURA - MarketBeat
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Kura Oncology (KURA) Q2 2026 Earnings Call Transcript - The Globe and Mail
Kura Oncology (NASDAQ: KURA) exec plans to sell 31,487 shares - Stock Titan
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Gains Traction With Its AML Menin Inhibitor - Kalkine Media
Troy Wilson Bought 12% More Shares In Kura Oncology - simplywall.st
Teleconferência de Resultados do 2º Trimestre de 2026 da Kura Oncology (KURA): Vendas do KOMZIFTI Atingem US$ 9,1 Milhões - TradingKey
Kura Oncology (NASDAQ:KURA) Hits New 52-Week High Following Insider Buying Activity - MarketBeat
Kura Oncology stock hits 52-week high at 12.49 USD - Investing.com
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect? - Yahoo Finance
Why Kura Oncology (KURA) Is Up 14.5% After New Ziftomenib Resistance Data And Q2 Results - Yahoo Finance
Kura Oncology stock rises on CEO insider purchase By Investing.com - Investing.com South Africa
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):